Peak nasal inspiratory flow and effect of dupilumab therapy in patients with severe CRSwNP from the SINUS-24 and SINUS-52 studies

被引：0
|
作者：
Desrosiers, M. [1 ]
Nash, S. [2 ]
Lane, A. [3 ]
Lee, S. [4 ]
De Corso, E. [5 ]
Xia, C. [2 ]
Khan, A. [6 ]
Jacob-Nara, J. [7 ]
Sacks, H. [2 ]
Rowe, P. [7 ]
Deniz, Y. [2 ]
机构：
[1] Univ Montreal, Div Otolaryngol Head & Neck Surg, Montreal, PQ, Canada
[2] Regeneron Pharmaceut Inc, Med Affairs, Tarrytown, NY USA
[3] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Div Otolaryngol Head & Neck Surg, Boston, MA USA
[5] A Gemelli Hosp Fdn IRCCS, Otorhinolaryngol Head & Neck Surg, Rome, Italy
[6] Sanofi, Global Med Affairs, Chilly Mazarin, France
[7] Sanofi, Global Med Affairs, Bridgewater, NJ USA
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P6.10
引用
收藏
页码：549 / 549
页数：1
相关论文
共 39 条
  • [31] Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
    Bachert, Claus
    Han, Joseph K.
    Desrosiers, Martin
    Hellings, Peter W.
    Amin, Nikhil
    Lee, Stella E.
    Mullol, Joaquim
    Greos, Leon S.
    Bosso, John V.
    Laidlaw, Tanya M.
    Cervin, Anders U.
    Maspero, Jorge F.
    Hopkins, Claire
    Olze, Heidi
    Canonica, G. Walter
    Paggiaro, Pierluigi
    Cho, Seong H.
    Fokkens, Wytske J.
    Fujieda, Shigeharu
    Zhang, Mei
    Lu, Xin
    Fan, Chunpeng
    Draikiwicz, Steven
    Kamat, Siddhesh A.
    Khan, Asif
    Pirozzi, Gianluca
    Patel, Naimish
    Graham, Neil M. H.
    Ruddy, Marcella
    Staudinger, Heribert
    Weinreich, David
    Stahl, Neil
    Yancopoulos, George D.
    Mannent, Leda P.
    LANCET, 2019, 394 (10209): : 1638 - 1650
  • [32] Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study
    Han, Joseph K.
    Bachert, Claus
    Desrosiers, Martin
    Laidlaw, Tanya M.
    Hopkins, Claire
    Fokkens, Wytske J.
    Paggiaro, Pierluigi
    Cho, Seong Ho
    Olze, Heidi
    Greos, Leon S.
    Zhang, Mei
    Fan, Chunpeng
    Draikiwicz, Steven
    Amin, Nikhil
    Kamat, Siddhesh
    Khan, Asif
    Pirozzi, Gianluca
    Graham, Neil M. H.
    Ruddy, Marcella
    Staudinger, Heribert
    Mannent, Leda P.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB422 - AB422
  • [33] Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019
    Bachert, C.
    Han, J. K.
    Desrosiers, M.
    LANCET, 2019, 394 (10209): : 1618 - 1618
  • [34] Dupilumab Reduces Blood, Urine, and Nasal Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyps in the Phase 3 SINUS-52 Trial
    Bachert, Claus
    Cho, Seong
    Laidlaw, Tanya
    Swanson, Brian
    Harel, Sivan
    Mannent, Leda
    Amin, Nikhil
    Jagerschmidt, Alexandre
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB185 - AB185
  • [35] Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial
    Bachert, Claus
    Mullol, Joaquim
    Daizadeh, Nadia
    Wolfe, Kelley
    Ortiz, Benjamin
    Johnson, Robert
    Deniz, Yamo
    Rowe, Paul
    Mannent, Leda
    Amin, Nikhil
    Harel, Sivan
    Jagerschmidt, Alexandre
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [36] Dupilumab is associated with lower rates of respiratory infections in patients with chronic rhinosinusitis with nasal polyps-Safety analysis from the SINUS-52 phase 3 trial
    Bachert, C.
    Gevaert, P.
    Lee, S. E.
    Kanesa-Thasan, N.
    Green, S.
    Mannent, L. P.
    Amin, N.
    Chen, Z.
    Lu, X.
    Pandit-Abid, N.
    Ortiz, B.
    ALLERGY, 2020, 75 : 225 - 226
  • [37] Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
    Maspero, Jorge F.
    Khan, Asif H.
    Philpott, Carl
    Hellings, Peter W.
    Hopkins, Claire
    Wagenmann, Martin
    Siddiqui, Shahid
    Msihid, Jerome
    Nash, Scott
    Chuang, Chien-Chia
    Kamat, Siddhesh
    Rowe, Paul J.
    Deniz, Yamo
    Jacob-Nara, Juby A.
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 323 - 332
  • [38] Health-Related Quality of Life Impairment Among Patients With Severe Chronic Rhinosinusitis With Nasal Polyps in the SINUS-24 Trial
    Maspero, Jorge
    Philpott, Carl
    Hellings, Peter
    Hopkins, Claire
    Wagenmann, Martin
    Siddiqui, Shahid
    Jacob-Nara, Juby
    Msihid, Jerome
    Chuang, Chien-Chia
    Kamat, Siddhesh
    Khan, Asif
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB133 - AB133
  • [39] Dupilumab treatment effects are observed after the first dose as measured at week 2 across atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps: Data from phase 3 SOLO 1 & 2, LIBERTY ASTHMA QUEST, and SINUS-52 studies
    Weidinger, S.
    Canonica, G. W.
    DesRosiers, M.
    Simpson, E. L.
    Bastian, M.
    Rice, M. S.
    Chen, Z.
    Mannent, L. P.
    Deniz, Y.
    Rowe, P.
    Amin, N.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 60 - 61
1234